CELEX: 62020TN0239
Language: en
Date: 2020-04-30 00:00:00
Title: Case T-239/20: Action brought on 30 April 2020 — Stada Arzneimittel v EUIPO — Pfizer (RUXXIMLA)

22.6.2020   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 209/37
            
         
      Action brought on 30 April 2020 — Stada Arzneimittel v EUIPO — Pfizer (RUXXIMLA)
      (Case T-239/20)
      (2020/C 209/48)
      Language in which the application was lodged: German
      
         Parties
      
      
         Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: J.-C. Plate and R. Kaase, lawyers)
      
         Defendant: European Union Intellectual Property Office (EUIPO)
      
         Other party to the proceedings before the Board of Appeal: Pfizer Inc. (New York, New York, United States)
      
         Details of the proceedings before EUIPO
      
      
         Applicant for the trade mark at issue: Applicant
      
         Trade mark at issue: Application for EU word mark RUXXIMLA — Application for registration No 17 865 742
      
         Procedure before EUIPO: Opposition proceedings
      
         Contested decision: Decision of the Fourth Board of Appeal of EUIPO of 13 February 2020 in Case R 1879/2019-4
      
         Form of order sought
      
      The applicant claims that the Court should:
      
                  —
               
               
                  annul the contested decision;
               
            
                  —
               
               
                  order EUIPO to pay the costs, including the costs of the appeal proceedings.
               
            
         Plea in law
      
      
                  —
               
               
                  Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council.